Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan

PURPOSE: Our preliminary report of imatinib mesylate (IM) in gastrointestinal stromal tumor (GIST) patients detailed a high response rate; however, the long-term result is still unknown. We conducted an analysis of Taiwan advanced inoperable/metastatic GIST patients treated on IM regarding survival,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yeh, Chun-Nan, Chen, Yen-Yang, Tseng, Jeng-Hwei, Chen, Jen-Shi, Chen, Tsung-Wen, Tsai, Chun-Yi, Cheng, Chi-Tung, Jan, Yi-Yin, Chen, Miin-Fu
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press Inc. 2011
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3243655/
https://ncbi.nlm.nih.gov/pubmed/22190996
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados